These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 27414067)
1. Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. Heffron TP J Med Chem; 2016 Nov; 59(22):10030-10066. PubMed ID: 27414067 [TBL] [Abstract][Full Text] [Related]
2. Challenges of developing small-molecule kinase inhibitors for brain tumors and the need for emphasis on free drug levels. Heffron TP Neuro Oncol; 2018 Feb; 20(3):307-312. PubMed ID: 29016919 [TBL] [Abstract][Full Text] [Related]
3. Targeting RSK: an overview of small molecule inhibitors. Nguyen TL Anticancer Agents Med Chem; 2008 Oct; 8(7):710-6. PubMed ID: 18855572 [TBL] [Abstract][Full Text] [Related]
4. Small molecules-Giant leaps for immuno-oncology. Kötzner L; Huck B; Garg S; Urbahns K Prog Med Chem; 2020; 59():1-62. PubMed ID: 32362326 [TBL] [Abstract][Full Text] [Related]
5. Small molecule kinase inhibitors as anti-cancer therapeutics. Chahrour O; Cairns D; Omran Z Mini Rev Med Chem; 2012 May; 12(5):399-411. PubMed ID: 22303944 [TBL] [Abstract][Full Text] [Related]
6. 25 years of small molecular weight kinase inhibitors: potentials and limitations. Fabbro D Mol Pharmacol; 2015 May; 87(5):766-75. PubMed ID: 25549667 [TBL] [Abstract][Full Text] [Related]
7. Kinase targets in CNS drug discovery. Gunosewoyo H; Yu L; Munoz L; Kassiou M Future Med Chem; 2017 Mar; 9(3):303-314. PubMed ID: 28176536 [TBL] [Abstract][Full Text] [Related]
8. A historical overview of protein kinases and their targeted small molecule inhibitors. Roskoski R Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888 [TBL] [Abstract][Full Text] [Related]
9. Leveraging Structural Diversity and Allosteric Regulatory Mechanisms of Protein Kinases in the Discovery of Small Molecule Inhibitors. Verkhivker GM Curr Med Chem; 2017; 24(42):4838-4872. PubMed ID: 27719654 [TBL] [Abstract][Full Text] [Related]
10. Synthetic Approaches and Clinical Application of Representative Small-Molecule Inhibitors of Cyclin-Dependent Kinase for Cancer Therapy. Wang YT; Jiang SQ; Zhang SL Molecules; 2024 Jun; 29(13):. PubMed ID: 38998978 [TBL] [Abstract][Full Text] [Related]
11. Recent advances in the discovery of small molecule c-Met Kinase inhibitors. Parikh PK; Ghate MD Eur J Med Chem; 2018 Jan; 143():1103-1138. PubMed ID: 29157685 [TBL] [Abstract][Full Text] [Related]
12. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview. Abate AA; Pentimalli F; Esposito L; Giordano A Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075 [TBL] [Abstract][Full Text] [Related]
13. Properties of FDA-approved small molecule protein kinase inhibitors. Roskoski R Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063 [TBL] [Abstract][Full Text] [Related]
14. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Jänne PA; Gray N; Settleman J Nat Rev Drug Discov; 2009 Sep; 8(9):709-23. PubMed ID: 19629074 [TBL] [Abstract][Full Text] [Related]
15. Recent advancement in developing small molecular inhibitors targeting key kinase pathways against triple-negative breast cancer. Islam R; Yen KP; Rani NN'M; Hossain MS Bioorg Med Chem; 2024 Oct; 112():117877. PubMed ID: 39159528 [TBL] [Abstract][Full Text] [Related]
16. Advancing the kinase field: new targets and second generation inhibitors. Laufer S; Bajorath J J Med Chem; 2015 Jan; 58(1):1. PubMed ID: 25490234 [No Abstract] [Full Text] [Related]